Avalo Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Avalo Therapeutics, Inc. - overview
Established
2011
Location
Rockville, MD, US
Primary Industry
Biotechnology
About
Based in Maryland, US, and founded in 2011, Cerecor, Inc. operates as a biopharmaceutical company that develops drugs for the treatment of cancer, autoimmune diseases, and rare genetic disorders. In June 2021, Cerecor, Inc. raised USD 20 million in venture debt financing led by Horizon Technology Finance.
As of 2021, the company is led by its CEO Michael Cola. The clinical-stage biotechnology firm focuses on the treatment of immune dysregulation by developing therapies. The firm is targeting the LIGHT signaling network. LIGHT is an immunoregulatory cytokine.
As of 2022, the firm is having two core programs for immune Dysregulation disorders in the pipeline which are AVTX-002 and AVTX-008. Another program named AVTX-803 is in pipeline with the mechanism of action of fucose replacement.
Current Investors
National Institute on Drug Abuse, Horizon Technology Finance, Armistice Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.avalotx.com/
Company Stage
Mature
Total Amount Raised
Subscriber access only
Avalo Therapeutics, Inc. - timeline of key events
Avalo Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | 1,152,987 | 27,813,137 | 18,326,801 | 6,750,351 | 6,698,615 | 5,398,000 | 18,051,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | 2312.3% | (34.1%) | (63.2%) | (0.8%) | (19.4%) | 234.4% | - | - | - |
| EBITDA (USD) | (10,986,439) | (16,053,191) | 14,453,358 | (34,458,230) | (12,120,925) | (65,382,207) | (80,497,000) | (37,294,000) | - | - | - |
| Operating Income (USD) | (11,009,947) | (16,080,047) | 13,889,982 | (39,313,766) | (16,111,763) | (67,225,385) | (82,154,000) | (37,460,000) | - | - | - |
| Operating Margin | - | (1394.6%) | 49.9% | (214.5%) | (238.7%) | (1003.6%) | (1521.9%) | (207.5%) | - | - | - |
| % EBITDA Margin | - | (1392.3%) | 52.0% | (188.0%) | (179.6%) | (976.1%) | (1491.2%) | (206.6%) | - | - | - |
| NET Income (USD) | (10,490,103) | (16,471,603) | 11,869,823 | (40,052,810) | (16,072,547) | (63,499,772) | (84,376,000) | (41,658,000) | - | - | - |
| % Net Margin | - | (1428.6%) | 42.7% | (218.5%) | (238.1%) | (948.0%) | (1563.1%) | (230.8%) | - | - | - |
Avalo Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.